| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 31 Oct 2025 | 17 Oct 2025 |
| Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2025 ,inter alia, to consider and approve Unaudited Financial Results (Standalone and Consolidated basis) for quarter and half year ended on 30th September, 2025 Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), and amendments thereto, this is to inform that the Meeting of the Board of Directors of the Company held today i.e., on Friday, 31st October, 2025, Board, inter-alia, considered and approved Un-Audited Financial Results (Standalone & Consolidated basis) for the Quarter and Half Year ended 30th September, 2025 along with Limited Review Report The Meeting was commenced at 04: 45 PM and concluded at 5:30 PM. (As Per BSE Announcement Dated on:31.10.2025) | ||
| Board Meeting | 29 Jul 2025 | 24 Jul 2025 |
| Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2025 inter alia to consider and approve The meeting of Board of Directors of the Company is scheduled to be held on Tuesday 29th July 2025 inter-alia to consider and approve the following: 1. The Unaudited Financial Results (Standalone & Consolidation basis) of the Company for the quarter ending on 30th June 2025 in accordance with Regulation 33 of the SEBI Listing Regulation. 2. Any other matter with the permission of the chair. As per attachment (As Per BSE Announcement Dated on: 29.07.2025) | ||
| Board Meeting | 14 May 2025 | 7 May 2025 |
| Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2025 inter alia to consider and approve Audited Standalone and Consolidated Financial Results for Quarter and Financial Year ended 31st March 2025 Due to typographical error, the company inadvertently mentioned wrong number in few lines of Financial results as mentioned in Annexure I. Please note that there is no change in broader head of Financials, internal numbers have been re-arranged Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), We would like to inform you that at the meeting of the Board of Directors of the Company held on Wednesday, 14th May 2025 which commenced at 1.30 p.m. and concluded at 4.00 p.m. have inter-alia, approved and taken on record as per the attachment Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March 2025 (As Per BSE Announcement Dated on :14.05.2025) | ||
| Board Meeting | 12 Feb 2025 | 24 Jan 2025 |
| Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2025 ,inter alia, to consider and approve 1. To consider and approve Unaudited Financial Results (Standalone & Consolidation basis) of the Company for the quarter ending on 31stDecember, 2025. Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), and amendments thereto, this is to inform that the Meeting of the Board of Directors of the Company held today i.e., on Wednesday, 12th February, 2025, Board, inter-alia, considered and approved the Unaudited Financial Results (Standalone & Consolidation basis) for the quarter and nine months ended 31st December, 2024. The Statutory Auditor has carried out a Limited Review of the Unaudited Financial Results for the quarter and nine months ended 31st December, 2024. Further, Pursuant to the Regulation 33 of the Listing Regulations, we are enclosing herewith a copy of the Unaudited Financial Results and Limited Review Report of the Statutory Auditors of the Company. The Meeting was commenced at 5:30 P.M. and concluded at 8:35 P.M Financial Results for Quarter and nine months ended 31st December, 2024 (As per BSE Announcement Dated on 12/02/2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.